Информативность предоперационных показателей ПСА в определении вероятности возникновения рецидива рака предстательной железы после радикальной простатэктомии

1. Brawer M.K., Benson M.C., Bostwick D.G. et al. Prostate-specific antigen and other serum markers: current concepts from the World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999; 17:206–21.

2. Chang S.S., Gaudin P.B., Reuter V.E., Heston W.D.W. Prostate-specific membrane antigen: present and future applications. Urology 2000; 55: 622–9.

3. Jensen O.M., Esteve J., Moller H., Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 26: 1167–256.

4. Black R.J., Bray F., Ferlay J., Parkin D.M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33:1075–107.

5. Данилова Т.В. Заболеваемость и смертность от злокачественных новообразований предстательной железы в России. Тезисы докл. IX Всероссийской конференции онкологов «Гормонозависимые опухоли»: СПб., 2002. с. 35–6.

6. Eastham J.A., Scardino P.T. Radical prostatectomy. In: Campbell’s Urology. Eds. P.S. Walsh et al. Philadelphia; 1999. p. 2547–64.

7. Gibbons R.P., Cole B.C., Richardson G. Adjuvant radiotherapy following radical prostate-ctomy: Results and complications. J Urol 1986;135: 65–8.

8. Myers R.P., Larson-Keller J.J., Bergstralh E.J. et al. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: Results of long term follow-up. Urology 1992; 174: 910–5.

9. Kent E.C., Hussain M.H.A. The rationale for adjuvant chemotherapy for high-risk prostate cancer. Curr Opin Urol 2003;13:123–31.